Exelixis, Inc. research snapshot
EXEL AI stock analysis reads Exelixis as a profitable oncology company built on the cabozantinib franchise, with rising free cash flow, aggressive share repurchases, and a high-stakes pipeline handoff to zanzalintinib. At the August 3, 2026 data cutoff, EXEL closed at $53.03 on July 31, 2026 with a verified market capitalization of about $13.33 billion. The stock pulled back about 8% from the $57.57 high set on July 7, 2026 ahead of second quarter earnings on August 5, 2026, after a non-significant STELLAR-303 non-liver-metastases readout in June. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$53.03
Market cap
$13.33 billion
AI score
68 / 100
Rating
Profitable cabo franchise with a mixed STELLAR-303 readout and a December 2026 PDUFA catalyst
Trend status
Short-term pullback below the 50-day average after the July 7 high, still above the 200-day average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Exelixis sells oncology medicines led by CABOMETYX (cabozantinib) in kidney, liver, thyroid, and neuroendocrine settings, with collaboration revenue and a next franchise candidate in zanzalintinib. | High |
| Moat | The moat comes from clinical evidence, label expansions in RCC and NET, specialist relationships, combination data with PD-1 and PD-L1 agents, and commercial scale in GU and GI oncology. It narrows if competitors match outcomes, the STELLAR-303 miss slows zanza positioning, or generics approach. | Medium |
| Management | CEO Michael Morrissey has led the company since 2010 through cabo commercialization, profitability, and buybacks totaling $2.59 billion since March 2023. A sixth repurchase program of up to $750 million was authorized in May 2026. | Medium-high |
| Financial trend | FY2025 revenue reached $2.320 billion with GAAP net income of $782.6 million. Q1 2026 total revenue was $610.8 million, GAAP net income $210.5 million, and non-GAAP diluted EPS $0.87. Management kept 2026 guidance for total revenue of $2.525 to $2.625 billion. | High |
| Valuation | At $53.03, EXEL traded near 17.5x trailing EPS of $3.02, 7.0x book value of $7.63, and 14.5x trailing free cash flow per share of $3.65, with an FCF yield near 6.9%. | High |
| Technical trend | Price sits below the StockAnalysis 50-day average near $53.57 and above the 200-day average near $45.79, with RSI near 41.6 and the 52-week range spanning about $33.76 to $57.57. | Medium |
| Risk level | Main risks are cabo concentration, loss of exclusivity and competitive pressure, the mixed STELLAR-303 NLM result, zanzalintinib regulatory and clinical outcomes, and short interest near 12.3% of shares outstanding with about 10.75 days to cover. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech catalysts and oncology competition can dominate any earnings model. | High data confidence |
| Investment certainty | Medium certainty. EXEL has a real cash engine and a defined next product path, but the stock still needs zanza approval and execution and durable cabo cash flows to support multi-year returns. | Medium |
EXEL AI stock forecast
The EXEL AI stock forecast uses scenario math around the $53.03 quote and consensus FY2026 EPS near $3.54. The 12-month framework produces a bullish area near $68 to $80, a base area near $50 to $60, and a bearish area near $40 to $46 before any major dilution, M&A, loss of exclusivity shock, or binary trial or FDA events.
$68 to $80
More likely if cabo demand keeps growing in RCC and NET, zanzalintinib gains FDA approval around the December 3, 2026 PDUFA window with a stronger-than-expected launch, STELLAR-304 reads out positive in the second half of 2026, and investors assign a low-20s multiple to consensus FY2027 EPS near $4.05.
$50 to $60
More likely if revenue grows near the low double digits, margins stay strong, buybacks continue, zanza is approved but launches at a measured pace, and the multiple stays near 14x to 17x consensus FY2026 EPS. This zone brackets the consensus analyst price target of $52.07.
$40 to $46
More likely if cabo growth stalls, loss of exclusivity or competitive TKIs and IO combos cut share, the STELLAR-303 NLM miss weakens zanza positioning, the PDUFA is delayed or the label is narrow, or the stock rerates toward a low-teens multiple while short interest stays elevated.
EXEL AI technical analysis
EXEL AI technical analysis is mixed as of the August 3, 2026 research cutoff using July 31 market data. StockAnalysis listed EXEL at $53.03, below the 50-day moving average near $53.57 and above the 200-day near $45.79, with RSI near 41.6 and a 52-week gain of about 44%. The stock fell 5.25% on July 31, 2026 ahead of August 5 earnings, so regaining the 50-day average matters before a fresh breakout attempt.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $53.03 | StockAnalysis close on July 31, 2026, used for market cap and valuation math. |
| Near support | $52.50 to $53 | The July 31 low near $52.79 is the first support zone after the pullback. |
| Secondary support | $50 to $51 | The late June trading zone near $50 to $51 is the next support band below the recent range. |
| Deeper support | $45.50 to $46 | The 200-day moving average near $45.79 marks the major trend support for the intermediate uptrend. |
| Moving averages | Mixed stack | Price is below the 50-day average near $53.57 but above the 200-day near $45.79, so the short-term trend has weakened while the longer trend holds. |
| Resistance | $55.50 to $56 | Recent trading highs near $55.97 to $56.18 are the first overhead supply zone. |
| Higher resistance | $57.60 | The July 7, 2026 52-week high near $57.57 is the main level the uptrend needs to break. |
| Momentum | Weakening | RSI near 41.6 shows momentum has shifted down from the over-60 readings in early July, without reaching an oversold extreme. |
| Volume | Event-sensitive mid-cap biotech volume | Average volume near 2.33 million shares. July 31 volume of about 3.03 million was elevated. Watch spikes around August 5 earnings, PDUFA news, and STELLAR-304 readouts. |
| Volatility | Moderate beta with binary event risk | Five-year beta near 0.42 understates event risk around FDA actions, earnings, and clinical oncology data. |
| Invalidation | Close below $50, then $45.79 | A decisive close below $50 weakens the swing setup. A close below the 200-day near $45.79 would force a deeper trend review. |
EXEL AI trading strategy
The EXEL AI trading strategy is a rules-based framework for a profitable mid-cap oncology stock with product concentration, buyback support, and binary pipeline catalysts. It is not personal advice and should be paired with live quotes, filings, position sizing, and event calendars.
Watch for EXEL to reclaim and hold the $53.50 to $54 zone above the 50-day average, then attempt a controlled break of the $55.50 to $56 resistance with confirming volume and no negative cabo, zanza, or earnings headlines.
A close below $50 should invalidate the short-term long swing. A close below $45.79 should force a full review of product growth, pipeline news, and valuation assumptions.
If EXEL pulls back toward $50 to $51 without a new clinical, competitive, regulatory, or earnings problem, compare the price move with cabo demand, cash and buybacks, and the zanza regulatory timeline.
Do not treat every pullback as mean reversion. Biotech support levels can fail quickly when PDUFA outcomes, trial readouts, or loss of exclusivity narratives change.
Track cabozantinib U.S. net product revenue, total revenue mix, gross and operating margins, free cash flow, cash and marketable securities, debt, share-count reduction from repurchases, zanzalintinib NDA status around the December 3, 2026 PDUFA, STELLAR-304 and Merck collaboration trial timing, and short interest.
Reduce confidence if valuation depends mainly on a premium multiple rather than durable cabo cash flow, successful zanza progression, and continued capital returns.
Investment research summary
Exelixis turns kinase-inhibitor science, clinical development, regulatory labels, and specialist oncology commercial execution into recurring medicine revenue, primarily through cabozantinib and its next-generation candidate zanzalintinib.
The moat is strongest where clinical data, combination regimens, label breadth in RCC and NET, physician familiarity, and commercial infrastructure reinforce each other. It narrows if rivals match survival outcomes, the STELLAR-303 miss slows zanza momentum, payers force net-price pressure, or loss of exclusivity approaches faster than zanza scales.
The thesis fails if cabo growth slows earlier than expected, competition or generics erode the cash engine before zanza launches, the December PDUFA or later trials disappoint after the non-significant NLM readout, capital returns slow, or the multiple compresses while earnings growth is still cabo-dependent.
Management has converted a single-franchise biotech into a profitable commercial company with repeated buybacks totaling $2.59 billion since March 2023. The next test is whether zanzalintinib becomes a second franchise while capital allocation stays disciplined across R&D, launch investment, and repurchases.
Oncology remains a long-duration growth field driven by combinations, biomarker segments, and oral targeted therapies. Exelixis sits in the multi-kinase inhibitor layer of GU and GI cancer care, where standards of care shift quickly as IO combos and next-generation TKIs evolve.
At roughly 17.5x trailing EPS and 14.5x free cash flow, EXEL is not priced like a pre-profit biotech, but the consensus price target near $52.07 shows limited upside at the current quote. Margin of safety improves if cabo cash flows stay high and zanza de-risks. It shrinks if loss of exclusivity or regulatory setbacks hit before earnings diversify.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| EXEL price | $53.03 close on July 31, 2026 | StockAnalysis statistics page | August 3, 2026 |
| Market capitalization | $13.33 billion, verified as $53.03 x 251.36 million shares (0.01% variance) | financial_rigor.py market cap verification and StockAnalysis | August 3, 2026 |
| Shares outstanding | 251.36 million, down 5.19% year over year | StockAnalysis and Morningstar cross-check | August 3, 2026 |
| FY2025 total revenue | $2.320 billion, up 6.98% from $2.169 billion in 2024 | Exelixis FY2025 earnings release | August 3, 2026 |
| FY2025 GAAP net income and diluted EPS | $782.6 million net income and $2.78 diluted EPS | Exelixis FY2025 earnings release | August 3, 2026 |
| FY2025 cabozantinib franchise U.S. net product revenues | $2.123 billion, with global franchise revenue of about $2.9 billion including partners | Exelixis FY2025 earnings release | August 3, 2026 |
| Q1 2026 results | $610.8 million total revenue, $555.0 million cabo U.S. net product revenues, $210.5 million GAAP net income, $0.79 GAAP diluted EPS, $0.87 non-GAAP diluted EPS | Exelixis Q1 2026 earnings release | August 3, 2026 |
| 2026 financial guidance | Total revenue $2.525 to $2.625 billion; net product revenues $2.325 to $2.425 billion; effective tax rate 21% to 23% | Exelixis Q1 2026 earnings release | August 3, 2026 |
| TTM valuation snapshot | TTM EPS $3.02, PE 17.54, PB 6.95, FCF per share $3.65, P/FCF 14.52, FCF yield 6.88%, EV/EBITDA 12.51 | StockAnalysis statistics and financial_rigor.py valuation check | August 3, 2026 |
| Cash and balance sheet | Cash $777 million, total debt $170 million, net cash $1.26 billion or $5.00 per share, book value $7.63 per share | StockAnalysis statistics page | August 3, 2026 |
| Technical averages and momentum | 50-day MA $53.57, 200-day MA $45.79, RSI 41.62, 52-week range $33.76 to $57.57, 52-week change +43.89% | StockAnalysis statistics page | August 3, 2026 |
| Short interest | 30.91 million shares short, 12.30% of shares outstanding, 15.12% of float, about 10.75 days to cover | StockAnalysis statistics page | August 3, 2026 |
| Stock repurchase activity | $2.59 billion repurchased since March 2023 retiring 86.8 million shares; $590.6 million bought in Q1 2026 at $43.14 average; additional $750 million program authorized in May 2026 | Exelixis Q1 2026 earnings release | August 3, 2026 |
| Zanzalintinib regulatory catalyst | FDA accepted NDA for zanzalintinib plus atezolizumab in previously treated mCRC with PDUFA target action date December 3, 2026 | Exelixis Q1 2026 earnings release | August 3, 2026 |
| STELLAR-303 NLM final analysis | Non-significant OS trend in the non-liver-metastases subgroup, stratified HR 0.83 (95% CI 0.66 to 1.05), P=0.1185; median OS 15.9 vs 12.7 months | Exelixis STELLAR-303 update press release | August 3, 2026 |
| Analyst consensus and financial forecast | Consensus Buy with average price target $52.07 across 19 analysts; FY2026 revenue consensus $2.60 billion and non-GAAP EPS $3.54 | StockAnalysis forecast page | August 3, 2026 |
This EXEL AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong if financial results, clinical data, regulation, competition, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
